title: Does slow-release 5-fluorouracil and triamcinolone reduce subglottic stenosis?
abstract: The surgical management of subglottic stenosis may be complicated by reformation of strictures. A slow-release combination of 5-fluorouracil, which has an antiproliferative effect on fibroblasts, and the corticosteroid triamcinolone acetonide has been used experimentally to control scar production in ophthalmic operations. This study was performed to determine if this material also can be used to reduce formation of subglottic stenosis. Subglottic stenosis was induced in rabbits by means of injury to the subglottic mucosa and submucosa. A suspension of the compound at a concentration of 2.5 mg/ml or 12.5 mg/ml was injected into the adjacent soft tissues. A control group of rabbits received the same volume of the suspension fluid but no compound. Two rabbits from each group were killed 1, 2, and 12 weeks postoperatively. No stenosis was seen at 1 or 2 weeks, but at 12 weeks the rate of formation of subglottic stenosis was decreased to a mean of 15.20% in the experimental groups compared with 47.37% in the control group. There were no indications of local or systemic toxicity. The promising results from this preliminary study suggest that use of this compound may reduce restenosis among patients treated surgically for subglottic stenosis. Further studies are being conducted.
authors.affiliation: Tufts University School of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Ingrams
authors.forename: S W
authors.initials: SW
authors.lastname: Sukin
authors.forename: P
authors.initials: P
authors.lastname: Ashton
authors.forename: H J
authors.initials: HJ
authors.lastname: Valtonen
authors.forename: M M
authors.initials: MM
authors.lastname: Pankratov
authors.forename: S M
authors.initials: SM
authors.lastname: Shapshay
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D002465:Cell Movement / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000494:pharmacology / Q000627:therapeutic use; D005347:Fibroblasts / Q000187:drug effects; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use*; D007829:Laryngostenosis / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D014221:Triamcinolone / Q000494:pharmacology / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D000964:Antimetabolites, Antineoplastic; D003692:Delayed-Action Preparations; D014221:Triamcinolone; D005472:Fluorouracil